Periorbital edema associated with alpelisib
Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination with fulvestrant. Hyperglycemia, rash, and gastroi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294222000867 |
| _version_ | 1818495197575643136 |
|---|---|
| author | Elizabeth A. Dao Saira J. George Meghan M. Heberton Omar Pacha Craig A. Kovitz Anisha B. Patel Rhea M. Phillips |
| author_facet | Elizabeth A. Dao Saira J. George Meghan M. Heberton Omar Pacha Craig A. Kovitz Anisha B. Patel Rhea M. Phillips |
| author_sort | Elizabeth A. Dao |
| collection | DOAJ |
| description | Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination with fulvestrant. Hyperglycemia, rash, and gastrointestinal upset are the most commonly reported adverse events associated with alpelisib. Although rash is a known on-target effect of alpelisib, patients typically present with a morbilliform rash. We describe two cases of periorbital edema associated with alpelisib. We discuss the clinical findings, management, and prognosis of this unique reaction. These cases highlight the importance of early involvement of dermatology to manage adverse cutaneous events associated with alpelisib. |
| first_indexed | 2024-12-10T18:17:18Z |
| format | Article |
| id | doaj.art-57706fab35ce41e3b986e7dc31f9d83e |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-12-10T18:17:18Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-57706fab35ce41e3b986e7dc31f9d83e2022-12-22T01:38:18ZengElsevierCancer Treatment and Research Communications2468-29422022-01-0132100596Periorbital edema associated with alpelisibElizabeth A. Dao0Saira J. George1Meghan M. Heberton2Omar Pacha3Craig A. Kovitz4Anisha B. Patel5Rhea M. Phillips6Louisiana State University Health Sciences Center School of Medicine, 2020 Gravier St., New Orleans, LA 70112, USA; Corresponding author.Department of Dermatology, Faculty Center Tower, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Floor 11, Box 1452, Houston, TX 77030, USA; Department of Dermatology, The University of Texas Health Science Center at Houston, 6655 Travis Street, Suite 700, Houston, TX 77030, USADepartment of Dermatology, Faculty Center Tower, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Floor 11, Box 1452, Houston, TX 77030, USADepartment of Dermatology, Faculty Center Tower, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Floor 11, Box 1452, Houston, TX 77030, USADepartment of Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USADepartment of Dermatology, Faculty Center Tower, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Floor 11, Box 1452, Houston, TX 77030, USA; Department of Dermatology, The University of Texas Health Science Center at Houston, 6655 Travis Street, Suite 700, Houston, TX 77030, USADepartment of Dermatology, Faculty Center Tower, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Floor 11, Box 1452, Houston, TX 77030, USA; Department of Dermatology, The University of Texas Health Science Center at Houston, 6655 Travis Street, Suite 700, Houston, TX 77030, USAAlpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination with fulvestrant. Hyperglycemia, rash, and gastrointestinal upset are the most commonly reported adverse events associated with alpelisib. Although rash is a known on-target effect of alpelisib, patients typically present with a morbilliform rash. We describe two cases of periorbital edema associated with alpelisib. We discuss the clinical findings, management, and prognosis of this unique reaction. These cases highlight the importance of early involvement of dermatology to manage adverse cutaneous events associated with alpelisib.http://www.sciencedirect.com/science/article/pii/S2468294222000867AlpelisibPhosphatidylinositol 3-kinase inhibitorsCutaneous adverse eventsBreast cancerDermatology |
| spellingShingle | Elizabeth A. Dao Saira J. George Meghan M. Heberton Omar Pacha Craig A. Kovitz Anisha B. Patel Rhea M. Phillips Periorbital edema associated with alpelisib Cancer Treatment and Research Communications Alpelisib Phosphatidylinositol 3-kinase inhibitors Cutaneous adverse events Breast cancer Dermatology |
| title | Periorbital edema associated with alpelisib |
| title_full | Periorbital edema associated with alpelisib |
| title_fullStr | Periorbital edema associated with alpelisib |
| title_full_unstemmed | Periorbital edema associated with alpelisib |
| title_short | Periorbital edema associated with alpelisib |
| title_sort | periorbital edema associated with alpelisib |
| topic | Alpelisib Phosphatidylinositol 3-kinase inhibitors Cutaneous adverse events Breast cancer Dermatology |
| url | http://www.sciencedirect.com/science/article/pii/S2468294222000867 |
| work_keys_str_mv | AT elizabethadao periorbitaledemaassociatedwithalpelisib AT sairajgeorge periorbitaledemaassociatedwithalpelisib AT meghanmheberton periorbitaledemaassociatedwithalpelisib AT omarpacha periorbitaledemaassociatedwithalpelisib AT craigakovitz periorbitaledemaassociatedwithalpelisib AT anishabpatel periorbitaledemaassociatedwithalpelisib AT rheamphillips periorbitaledemaassociatedwithalpelisib |